Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 22 October 2017

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

NIH consensus on antiviral therapy for adults with chronic Hep B

This month’s Annals of Internal Medicine reports on the National Institutes of Health Consensus Development Conference on antiviral therapy for chronic Hep B.

News image

fiogf49gjkf04

Chronic Hepatitis B infection can lead to liver failure, hepatocellular carcinoma, and death.

Dr Tatyana Shamliyan and colleagues evaluated the effectiveness of antiviral therapy for adults with chronic Hepatitis B infection.

The team identified randomized, controlled trials of interferon, lamivudine, adefovir, entecavir, and telbivudine published from 1990 to 2008.

In addition, randomized, controlled clinical trials of adults with chronic Hepatitis B published in English after 1989 that reported death were assessed.

The team recorded the incidence of hepatocellular carcinoma or liver failure, prevalence and incidence of cirrhosis.

The presence or seroconversion of Hepatitis B e antigen or surface antigen, viral load of Hepatitis B virus DNA was also recorded.

Drug treatment did not improve clinical outcomes of chronic Hep B
Annals of Internal Medicine

The team measured aspartate aminotransferase and alanine aminotransferase levels.

Fibrosis scores after therapy with interferon-2b, pegylated interferon-2a, lamivudine, adefovir, entecavir, and telbivudine was assessed.

The team extracted data with standard protocols to calculate risk difference for clinical outcomes, viral load, Hepatitis B e antigen or surface antigen, alanine aminotransferase levels, histologic scores, and adverse events.

In 16 randomized controlled trials including 4431 patients, drug treatment did not improve clinical outcomes of chronic Hepatitis B infection.

However, the team reported that the trials were underpowered.

In 60 randomized controlled trials that examined intermediate outcomes, the team found no single treatment improved all intermediate outcomes.

Low-quality evidence suggested Hepatitis B e surface antigen clearance after interferon-2b, including 2 randomized controlled trials of 211 patients.

The team found that moderate-quality evidence suggested alanine aminotransferase levels normalization at follow-up after treatment with adefovir, and Hepatitis B e antigen loss with lamivudine.

With interferon-2b, moderate-quality evidence suggested Hepatitis B e antigen loss, seroconversion, and alanine aminotransferase levels normalization.

Pegylated interferon-2a versus lamivudine improved Hepatitis B e antigen seroconversion, and alanine aminotransferase levels normalization off treatment.

The team observed that pegylated interferon-2a combined with lamivudine versus lamivudine improved Hepatitis B e antigen loss, and alanine aminotransferase levels normalization.

Adverse events during antiretroviral therapy occurred in more than 50% of patients, but were not associated with increased treatment discontinuation.

However, the research team noted that most studies excluded patients with hepatic or renal insufficiency or other serious comorbid conditions.

Dr Shamliyan’s team concludes, “Evidence was insufficient to assess treatment effect on clinical outcomes or determine whether inconsistent improvements in selected intermediate measures are reliable surrogates.”

“Future research is needed to provide evidence-based recommendations about optimal antiviral therapy in adults with chronic Hepatitis B infection.”  

Ann Int Med 2009: 150(2)


08 January 2009

Go to top of page Email this page Email this page to a colleague

 20 October 2017 
Hospital readmissions reduction program
 20 October 2017 
Conversion of planned colonoscopy to sigmoidoscopy
 20 October 2017 
Food elimination diets for treatment of adults with eosinophilic esophagitis
 19 October 2017 
Fecal immunochemical tests in colorectal cancer screening
 19 October 2017 
Surgical anastomosis at 1-year colorectal cancer surveillance
 19 October 2017 
Current management of chylous ascites
 18 October 2017 
Hep E seroprevalence and hemodialysis
 18 October 2017 
Prebiotic and changes in the human gut microbiota
 18 October 2017 
Predicting recurrence after curative rectal cancer surgery
 17 October 2017 
Laparoscopic surgery use in Medicare patients with colon cancer
 17 October 2017 
Medication nonadherence and health care costs
 17 October 2017 
Asthma and IBD development
 16 October 2017 
Colorectal cancer screening and postpolypectomy surveillance colonoscopy
 16 October 2017 
Continuity of care after colorectal surgery
 16 October 2017 
Breastfeeding and the risk of IBD
 13 October 2017 
Treating patients with HCV and severe renal impairment
 13 October 2017 
Blood pressure management during abdominal surgery
 13 October 2017 
Food elimination diets for eosinophilic esophagitis
 12 October 2017 
Global recurrence of H. pylori
 12 October 2017 
Colonoscopy in an organized colorectal cancer screening program 
 12 October 2017 
Predicting advanced fibrosis in chronic hepatitis B
 11 October 2017 
Fecal microbiota transplantation for ulcerative colitis
 11 October 2017 
Sexual functioning in Hep C
 11 October 2017 
Ulcerative proctitis in pediatric-onset UC
 10 October 2017 
Quality standards in upper gastrointestinal endoscopy
 10 October 2017 
Eosinophilic esophagitis and swallowed topical corticosteroids
 10 October 2017 
Follow-up of positive results on fecal blood tests
 09 October 2017 
Diverticulitis and emergency department burden
 09 October 2017 
Global recurrence rate of H. pylori
 09 October 2017 
Clostridium difficile infection after ileostomy reversal
 06 October 2017 
Predicting nontreatment for Hep C
 06 October 2017 
Cow's milk–based formula and development of celiac disease
 06 October 2017 
Propofol for outpatient colonoscopy
 05 October 2017 
Pediatric candidates on the transplant wait list
 05 October 2017 
Incidence of sepsis in the USA
 05 October 2017 
Quality of life after chemoradiation in rectal cancer
 04 October 2017 
Peptic ulcer disease diagnosed in acute upper endoscopy
 04 October 2017 
Clinical practice guidelines in colon cancer
 04 October 2017 
Rural residence and risk of IBD
 03 October 2017 
Novel candidate risk genes for IBD
 03 October 2017 
Antibody tests and detecting celiac disease
 03 October 2017 
Environmental factors and IBD
 02 October 2017 
Full publication of Gastroenerology abstracts
 02 October 2017 
Interferon-free therapy in advanced liver disease
 02 October 2017 
Burden of NAFLD with advanced fibrosis in the USA
 29 September 2017 
Inpatient Gastroenterology training experience
 29 September 2017 
Proteomic analysis of IBD
 28 September 2017 
Social networking-based discussion group by ERCP doctors
 28 September 2017 
Incidence of biopsy-verified celiac disease
 27 September 2017 
Predictors of nonadherence in IBD
 27 September 2017 
Hep C treatment in the era of direct-acting anti-viral agents
 27 September 2017 
Function of trypsin-3 in IBS
 26 September 2017 
Chronic pancreatitis and pancreatic cancer risk
 26 September 2017 
Factors associated with the risk of metachronous gastric neoplasm
 26 September 2017 
Treatment of hyperactive delirium in advanced cancer
 25 September 2017 
Lenalidomide for advanced liver cancer
 25 September 2017 
Silibinin nanoparticles inhibit HCV infection
 22 September 2017 
MRI for liver metastatic colorectal cancer
 22 September 2017 
Perforation after colonic endoscopic mucosal resection
 22 September 2017 
Medical management and colectomy rates

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2017 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us